ZUMA-2
ZUMA-2 showed that CD19 CAR-T cells could produce deep and lasting remissions in mantle cell lymphoma that had stopped responding to BTK inhibitors, a group that previously had few options.
Overview
ZUMA-2 was a single-arm phase 2 study of brexucabtagene autoleucel (KTE-X19), a CD19-directed CAR-T manufactured with a process that removes circulating lymphoma cells, in patients with relapsed or refractory mantle cell lymphoma after up to five prior therapies including a BTK inhibitor. The primary endpoint was objective response rate by independent review.
Most treated patients responded and a majority achieved complete remission, with durable responses in a substantial share at long follow-up, including patients with TP53 mutations and blastoid morphology. Cytokine release syndrome and neurological events were common but largely reversible. The product was approved in the United States in July 2020, the first CAR-T for mantle cell lymphoma.
Similar pages
not linked directly; found by shared links- TrialZUMA-1
Shares Gilead Sciences (incl. Kite), Non-Hodgkin lymphoma (all types) and the tag subtype-trials.
- TrialZUMA-5
Shares Gilead Sciences (incl. Kite), Non-Hodgkin lymphoma (all types) and the tag subtype-trials.
- TrialASPEN (Waldenström macroglobulinaemia)
Shares Non-Hodgkin lymphoma (all types) and the tag subtype-trials.
- TrialAUGMENT
Shares Non-Hodgkin lymphoma (all types) and the tag subtype-trials.
- TrialECHELON-2
Shares Non-Hodgkin lymphoma (all types) and the tag subtype-trials.
- TrialStudy of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic L
Shares Brexucabtagene autoleucel, Gilead Sciences (incl. Kite), Mantle cell lymphoma.
- Key paperZUMA-2: brexu-cel CAR-T for mantle cell lymphoma that has failed BTK inhibitors
Shares Michael L. Wang, Brexucabtagene autoleucel, Gilead Sciences (incl. Kite), Mantle cell lymphoma.
- TrialA Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Shares Mantle cell lymphoma, Non-Hodgkin lymphoma (all types).